Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,410 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,410 shares of Natera stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the sale, the insider directly owned 129,019 shares in the company, valued at approximately $34,264,866.02. This represents a 2.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The stock was sold at an average price of $254.07, for a total value of $305,900.28.
• On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The stock was sold at an average price of $260.49, for a total transaction of $263,094.90.
• On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $272.90, for a total transaction of $818,700.00.
• On Monday, June 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $218.43, for a total transaction of $655,290.00.
• On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The stock was sold at an average price of $202.84, for a total transaction of $335,091.68.

Natera Trading Down 0.2%

Natera stock opened at $274.58 on Thursday. Natera, Inc. has a 1-year low of $135.75 and a 1-year high of $288.04. The company has a fifty day simple moving average of $251.03 and a 200 day simple moving average of $222.85. The company has a market cap of $39.32 billion, a P/E ratio of -168.45 and a beta of 1.51.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera filed with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval of its Signatera test for bladder cancer. Approval would expand the addressable market for the company’s molecular residual disease testing and could support additional international revenue growth. Natera Files for Japan PMDA Approval of Signatera Test in Bladder Cancer
• Neutral Sentiment: Natera reported sales by CEO Steven Leonard Chapman, CFO Michael Burkes Brophy, and executives Solomon Moshkevich and John Fesko totaling approximately 7,576 shares and $2.02 million. Each sale was executed under a pre-arranged Rule 10b5-1 plan and was made to cover tax withholding obligations from vested equity awards. The executives retained substantial positions, reducing the significance of the transactions as a signal of weakening confidence.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Wolfe Research initiated coverage on Natera in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 target price on the stock. Canaccord Genuity Group raised their price target on Natera from $285.00 to $330.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. William Blair began coverage on Natera in a research report on Tuesday, April 14th. They set an “outperform” rating on the stock. Wall Street Zen cut Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Royal Bank Of Canada assumed coverage on Natera in a research note on Thursday, June 11th. They set an “outperform” rating and a $275.00 price objective on the stock. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus price target of $267.83.

Institutional Investors Weigh In On Natera

Several hedge funds have recently bought and sold shares of the company. Reflection Asset Management bought a new stake in Natera in the fourth quarter valued at approximately $29,000. Elevation Wealth Partners LLC acquired a new stake in shares of Natera in the second quarter valued at approximately $30,000. Palladiem LLC bought a new position in shares of Natera during the 4th quarter worth approximately $31,000. Horizon Investments LLC bought a new position in shares of Natera during the 3rd quarter worth approximately $32,000. Finally, International Assets Investment Management LLC increased its holdings in shares of Natera by 132.9% during the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after acquiring an additional 97 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.